BACKGROUND. Zidovudine has been shown to prolong survival in patients with the acquired immunodeficiency syndrome (AIDS) and, in persons with human immunodeficiency virus (HIV) infection but not AIDS, to delay the progression to AIDS. However, it is still uncertain whether treatment before the development of AIDS prolongs survival. METHODS. We analyzed data from a cohort of 2162 high-risk men who were already seropositive for HIV type 1 (HIV-1) and 406 men who seroconverted from October 1986 through April 1991. There were 306 deaths. The probabilities of death were compared among men at similar stages of disease who began zidovudine therapy before the diagnosis of AIDS and among those who did not. Relative risks of death were calculated for each of five initial disease states on the basis of CD4+ cell counts and clinical symptoms and signs appearing over follow-up periods of 6, 12, 18, and 24 months. Adjustments were also made for the use of prophylaxis against Pneumocystis carinii pneumonia (PCP). RESULTS. After we controlled for CD4+ cell count and symptoms, the use of zidovudine with or without PCP prophylaxis before the development of AIDS significantly reduced mortality in all follow-up periods. The relative risks of death were 0.43 (95 percent confidence interval, 0.23 to 0.78) at 6 months, 0.54 (95 percent confidence interval, 0.38 to 0.78) at 12 months, 0.59 (95 percent confidence interval, 0.44 to 0.79) at 18 months, and 0.67 (95 percent confidence interval, 0.52 to 0.86) at 24 months. After we adjusted for the effects of PCP prophylaxis, zidovudine alone significantly reduced mortality at 6, 12, and 18 months (relative risks, 0.45, 0.59, and 0.70, respectively), but not at 24 months (relative risk, 0.81). Among zidovudine users, those who also used PCP prophylaxis before the development of AIDS had significantly lower mortality at 18 and 24 months than those who did not (relative risks, 0.62 and 0.60, respectively). CONCLUSIONS. The results of this study support the hypothesis that in HIV-1 infection, early treatment with zidovudine and PCP prophylaxis improves survival in addition to slowing the progression to AIDS.
Source Information
Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205.
This article has been cited by other articles:
Holkova, B., Takeshita, K., Cheng, D. M., Volm, M., Wasserheit, C., Demopoulos, R., Chanan-Khan, A.
(2001). Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi's Sarcoma Treated With Chemotherapy. JCO
19: 3848-3851
[Abstract][Full Text]
Ahdieh, L., Gange, S. J., Greenblatt, R., Minkoff, H., Anastos, K., Young, M., Nowicki, M., Kovacs, A., Cohen, M., Munoz, A.
(2000). Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus. Am J Epidemiol
152: 923-933
[Abstract][Full Text]
Hendriks, J. C., Craib, K. J., Veugelers, P. J, van Druten, H. A., Coutinho, R. A, Schechter, M. T, van Griensven, G. J.
(2000). Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model. Int J Epidemiol
29: 565-572
[Abstract][Full Text]
Paltiel, A. D., Freedberg, K. A.
(1998). The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces
28: 34-51
[Abstract]
Owens, D. K., Brandeau, M. L., Sox, C. H.
(1998). Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus. Interfaces
28: 52-74
[Abstract]
Paltiel, A. D., Scharfstein, J. A., Seage, G. R., Losina, E., Goldie, S. J., Weinstein, M. C., Craven, D. E., Freedberg, K. A.
(1998). A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection. Med Decis Making
18: S93-S105
[Abstract]
Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G.
(1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA
279: 450-454
[Abstract][Full Text]
Moore, R. D., Keruly, J. C., Chaisson, R. E.
(1996). Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection. Arch Intern Med
156: 1073-1077
[Abstract]
Enger, C., Graham, N., Peng, Y., Chmiel, J. S., Kingsley, L. A., Detels, R., Munoz, A.
(1996). Survival From Early, Intermediate, and Late Stages of HIV Infection. JAMA
275: 1329-1334
[Abstract]
Kitahata, M. M., Koepsell, T. D., Deyo, R. A., Maxwell, C. L., Dodge, W. T., Wagner, E. H.
(1996). Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival. NEJM
334: 701-707
[Abstract][Full Text]
Owens, D. K., Nease, R. F. Jr, Harris, R. A.
(1996). Cost-effectiveness of HIV Screening in Acute Care Settings. Arch Intern Med
156: 394-404
[Abstract]
Laraque, F., Greene, A., Triano-Davis, J. W., Altman, R., Lin-Greenberg, A.
(1996). Effect of Comprehensive Intervention Program on Survival of Patients With Human Immunodeficiency Virus Infection. Arch Intern Med
156: 169-176
[Abstract]
Chaisson, R. E., Keruly, J. C., Moore, R. D.
(1995). Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease. NEJM
333: 751-756
[Abstract][Full Text]
Franklin, C., Friedman, Y., Wong, T., Hu, T.-C.
(1995). Improving Long-term Prognosis for Survivors of Mechanical Ventilation in Patients With AIDS With PCP and Acute Respiratory Failure: Five-Year Follow-up of Intensive Care Unit Discharges. Arch Intern Med
155: 91-95
[Abstract]
Rossi, S., Whitfeld, M., Berger, T. G.
(1995). The Treatment of Acyclovir-Resistant Herpes Zoster With Trifluorothymidine and Interferon Alfa. Arch Dermatol
131: 24-26
[Abstract]
Musicco, M., Lazzarin, A., Nicolosi, A., Gasparini, M., Costigliola, P., Arici, C., Saracco, A., Italian Study Group on HIV Heterosexual Transmissi,
(1994). Antiretroviral Treatment of Men Infected With Human Immunodeficiency Virus Type 1 Reduces the Incidence of Heterosexual Transmission. Arch Intern Med
154: 1971-1976
[Abstract]
Turner, B. J., Hecht, F. M., Ismail, R. B.
(1994). CD4+ T-Lymphocyte Measures in the Treatment of Individuals Infected With Human Immunodeficiency Virus Type 1: A Review for Clinical Practitioners. Arch Intern Med
154: 1561-1573
[Abstract]
Markson, L. E., Cosler, L. E., Turner, B. J.
(1994). Implications of Generalists' Slow Adoption of Zidovudine in Clinical Practice. Arch Intern Med
154: 1497-1504
[Abstract]
Gostin, L. O., Lazzarini, Z., Alexander, D., Brandt, A. M., Mayer, K. H., Silverman, D. C.
(1994). HIV Testing, Counseling, and Prophylaxis After Sexual Assault. JAMA
271: 1436-1444
[Abstract]
Duvic, M., Crane, M. M., Conant, M., Mahoney, S. E., Reveille, J. D., Lehrman, S. N.
(1994). Zidovudine Improves Psoriasis in Human Immunodeficiency Virus--Positive Males. Arch Dermatol
130: 447-451
[Abstract]
Fein, J. A., Friedland, L. R., Rutstein, R., Bell, L. M.
(1993). Children With Unrecognized Human Immunodeficiency Virus Infection: An Emergency Department Perspective. Arch Pediatr Adolesc Med
147: 1104-1108
[Abstract]
Gerber, A. R., Valdiserri, R. O., Holtgrave, D. R., Jones, T. S., West, G. R., Hinman, A. R., Curran, J. W.
(1993). Preventive Services Guidelines for Primary Care Clinicians Caring for Adults and Adolescents Infected With the Human Immunodeficiency Virus. Arch Fam Med
2: 969-979
[Abstract]
Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D, Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., Fiddian, A. P., The European-Australian Collaborative Group,
(1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. NEJM
329: 297-303
[Abstract][Full Text]
Vermund, S. H.
(1993). Rising HIV-Related Mortality in Young Americans. JAMA
269: 3034-3035
[Abstract]
Johnston, M., Hoth, D.
(1993). Present status and future prospects for HIV therapies. Science
260: 1286-1293
[Abstract]
Jewett, J. F., Hecht, F. M.
(1993). Preventive Health Care for Adults With HIV Infection. JAMA
269: 1144-1153
[Abstract]
Chaisson, R. E., Keruly, J., Richman, D. D., Moore, R. D.
(1992). Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine. Arch Intern Med
152: 2009-2013
[Abstract]
McLeod, G. X., Hammer, S. M.
(1992). Zidovudine: Five Years Later. ANN INTERN MED
117: 487-501
[Abstract]
(1992). EARLY TREATMENT EXTENDS SURVIVAL IN HIV INFECTION. JWatch General
1992: 1-1
[Full Text]
